Related Experiment Video

Updated: Apr 16, 2026

Osmotic Pump-based Drug-delivery for In Vivo Remyelination Research on the Central Nervous System
06:07

Osmotic Pump-based Drug-delivery for In Vivo Remyelination Research on the Central Nervous System

Published on: December 17, 2021

6.2K

Anti-muscarinic adjunct therapy accelerates functional human oligodendrocyte repair

Kavitha Abiraman1, Suyog U Pol2, Melanie A O'Bara2

  • 1Neuroscience Program.

The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|February 27, 2015
PubMed

Insights

Researchers found that blocking M3R muscarinic receptors accelerates human oligodendrocyte progenitor (hOPC) differentiation. This discovery offers a new therapeutic strategy for myelin repair in neurological disorders.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Pharmacology

Background:

  • Therapeutic remyelination for myelin disorders is hindered by slow human oligodendrocyte differentiation.
  • Identifying pharmacological targets to accelerate this process is crucial for effective treatment.

Purpose of the Study:

  • To identify and validate pharmacological targets for accelerating human oligodendrocyte progenitor (hOPC) differentiation.
  • To investigate the role of muscarinic acetylcholine receptors in hOPC differentiation.

Main Methods:

  • Utilized fluorescence-activated cell sorting (FACS) and microarray analysis to identify hOPC-specific receptors.
  • Treated hOPCs with muscarinic agonists and antagonists, including solifenacin.
  • Administered solifenacin to hypomyelinated shiverer/rag2 mouse models with transplanted hOPCs.

Main Results:

  • Identified CHRM3 (M3R) as an oligodendrocyte-biased receptor on hOPCs.
  • Muscarinic agonist treatment blocked hOPC differentiation, while M3R antagonist treatment stimulated it.
  • Systemic solifenacin treatment enhanced oligodendrocyte differentiation and improved nerve conduction velocity in vivo.

Conclusions:

  • Selective muscarinic antagonists, such as solifenacin, can accelerate hOPC differentiation.
  • These antagonists represent promising adjunct therapies for promoting myelin repair in neurological conditions.
  • Targeting M3R offers a novel approach to enhance the efficacy of progenitor cell transplantation.
Keywords:
gliahumanmicroarrayoligodendrocyte

More Related Videos

Generation of Human Neurons and Oligodendrocytes from Pluripotent Stem Cells for Modeling Neuron-Oligodendrocyte Interactions10:53

Generation of Human Neurons and Oligodendrocytes from Pluripotent Stem Cells for Modeling Neuron-Oligodendrocyte Interactions

Published on: November 9, 2020

5.8K
Preparation of Rat Oligodendrocyte Progenitor Cultures and Quantification of Oligodendrogenesis Using Dual-infrared Fluorescence Scanning11:11

Preparation of Rat Oligodendrocyte Progenitor Cultures and Quantification of Oligodendrogenesis Using Dual-infrared Fluorescence Scanning

Published on: February 17, 2016

12.6K

Related Concept Videos

Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.8K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
2.1K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.9K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
1.1K
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.6K